US$ 24.58
bpc-157 fda warning letter unapproved new drug of the Federal Food, Drug, and Cosmetic Act (FDCA).* FDA mulls compounding for peptides
Description
Use only in properly equipped laboratory settings with appropriate personal protective equipment.

BPC-157 has extensive preclinical literature : Animal and cell studies suggest potential roles in tissue repair and inflammation modulation

[DOI] [PMC free article] [PubMed] [Google Scholar] 59.Zhou Z., Song W., Zhang G., Zhan S., Cai Z., Yu W., He Y

Still, researchers with active malignancy are generally advised to avoid telomerase-activating compounds until more definitive safety data becomes available
